snake online game

Public Sector Pension Investment Board Purchases 1,400 Shares of International Flavors & Fragrances Inc. (NYSE:IFF)Phase 3 Study Results Demonstrated Three Year, Disease-Free Survival of 96% THOUSAND OAKS, Calif. , Dec. 7, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data demonstrating that adding BLINCYTO ® (blinatumomab) to chemotherapy significantly improves disease-free survival (DFS) in newly diagnosed pediatric patients with National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL) of average or higher risk of relapse. The data are from a Phase 3 study (AALL1731) conducted by the Children's Oncology Group. The results were simultaneously published in the New England Journal of Medicine and will be presented during the plenary session on Sunday, Dec. 8 , at 2 p.m. PT at the 66 th American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego . "Over the last decade, BLINCYTO has reshaped the treatment landscape for B-ALL, offering a critical lifeline for thousands of adult and pediatric patients," said Jay Bradner , M.D., executive vice president of Research and Development and chief scientific officer at Amgen. "These powerful new data leave us little doubt about the profound impact of this medicine for a large number of children affected by this disease. We are grateful to the Children's Oncology Group, along with the patients, families and clinical teams, for their dedication and partnership in advancing this critical study to improve the lives of children with cancer." Based on the results of the first pre-specified interim analysis for efficacy, the study met its primary endpoint of DFS and study randomization was terminated early based on the recommendation from the data and safety monitoring committee due to the benefit observed in the BLINCYTO arm compared to the chemotherapy-only arm. Overall, the 3-year DFS was 96.0% for patients treated with chemotherapy plus BLINCYTO compared to 87.9% for those treated with only chemotherapy. The hazard ratio (HR) was 0.39 [95% confidence interval (CI) 0.24-0.64], indicating a 61% reduction in the risk of disease relapse, secondary malignant neoplasm or remission death with BLINCYTO. At 3 years, more patients remained alive and cancer free when treated with BLINCYTO plus chemotherapy compared to chemotherapy alone. "The AALL1731 study results are truly practice-changing, further solidifying blinatumomab's role as the standard of care for a large number of children with B-ALL," said Sumit Gupta , M.D., Ph.D., FRCPC, co-chair of the Children's Oncology Group AALL1731 study and oncologist and clinician investigator, Division of Haematology/Oncology at The Hospital for Sick Children (SickKids) and associate professor of pediatrics at the University of Toronto . "These breakthrough data showing a significant improvement in disease-free survival are poised to bring substantial clinical value to children with newly diagnosed B-ALL." The addition of BLINCYTO to chemotherapy in standard risk patients resulted in outcomes similar to those previously achieved in only the most favorable pediatric risk subsets. Among SR-Average patients, 3-year DFS was 97.5% for patients treated with BLINCYTO compared to 90.2% for those treated with only chemotherapy (HR 0.33, CI 0.15-0.69). For SR-High patients, 3-year DFS was 94.1% for those treated with BLINCYTO compared to 84.8% for those treated with only chemotherapy (HR 0.45, 95% CI 0.24-0.85). "Relapsed ALL remains a major cause of pediatric cancer mortality, with nearly half of the relapses occurring in children with standard-risk B-ALL," said Rachel E. Rau , M.D., co-chair of the Children's Oncology Group AALL1731 study, pediatric hematologist-oncologist at Seattle Children's Hospital and associate professor of pediatrics at the University of Washington . "These findings underscore the progress made with blinatumomab in preventing relapse and support its role as a critical addition to current therapeutic strategies." Safety results are consistent with the known safety profile of BLINCYTO. BLINCYTO has demonstrated a positive balance of benefits and risks, with only 0.3% of first courses associated with Grade 3+ cytokine release syndrome (CRS) and 0.7% with seizures. A higher risk of infections was observed in the BLINCYTO arm. These results provide the first evidence supporting BLINCYTO for use in the consolidation phase in newly diagnosed pediatric Philadelphia chromosome-negative (Ph-) B-ALL patients. This groundbreaking first-in-class Bispecific T-cell Engager (BiTE ® ) therapy is now backed by additional evidence reinforcing its role in redefining a standard of care for both adult and pediatric patients, starting from one month old, regardless of measurable residual disease (MRD) status. The findings further establish BLINCYTO as a versatile first-line consolidation therapy across all ages and treatment backbones. The NCI's Cancer Therapy Evaluation Program (CTEP), which sponsored the study will share data with the U.S. Food and Drug Administration as part of their ongoing communications relating to the trial. About The Children's Oncology Group The Children's Oncology Group (childrensoncologygroup.org), a member of the NCI National Clinical Trials Network (NCTN), is the world's largest organization devoted exclusively to childhood and adolescent cancer research. The Children's Oncology Group unites over 10,000 experts in childhood cancer at more than 200 leading children's hospitals, universities and cancer centers across North America , Australia , New Zealand and Saudi Arabia in the fight against childhood cancer. Today, more than 80% of the 15,000 children and adolescents diagnosed with cancer each year in the United States are cared for at Children's Oncology Group member institutions. Research performed by Children's Oncology Group institutions over the past 50 years has transformed childhood cancer from a virtually incurable disease to one with a combined 5-year survival rate of 86%. The Children's Oncology Group's mission is to improve the cure rate and outcomes for all children with cancer. About AALL1731 (NCT03914625) The AALL1731 study was a Phase 3 randomized trial to determine if two non-sequential cycles of BLINCYTO added to chemotherapy improved disease-free survival (DFS) in children with newly diagnosed pediatric National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL). The study enrolled 4,264 newly diagnosed NCI SR B-ALL patients, of whom 2,334 were risk stratified at the end of induction therapy as either SR-Average or SR-High. At the first planned interim efficacy analysis (data cutoff June 30, 2024 ), 1,440 of the eligible and evaluable patients had been randomized. The AALL1731 study was designed and conducted independently from industry. The Cancer Therapy Evaluation Program (CTEP) of the NCI sponsored the trial and provided funding to the Children's Oncology Group to conduct the study. NCI is part of the National Institutes of Health (NIH). In addition, Amgen provided BLINCYTO and support through an NCI Cooperative Research and Development Agreement. About Acute Lymphoblastic Leukemia (ALL) ALL, also known as acute lymphoblastic leukemia, is a fast-growing type of blood cancer that develops in the bone marrow and can sometimes spread to other parts of the body, including the lymph nodes, liver, spleen and central nervous system. ALL is a rare disease, with an estimated 6,550 new cases, affecting both children and adults, diagnosed in the U.S. in 2024. 1 B-ALL begins in immature cells that would normally develop into B-cell lymphocytes, which are white blood cells that grow in bone marrow. 2,3 B-ALL is the most common type of ALL, constituting approximately 75% of cases in adults and approximately 88% in children, the most common cancer in children. 4,5 About BLINCYTO ® (blinatumomab) BLINCYTO is the first globally approved Bispecific T-cell Engager (BiTE ® ) immuno-oncology therapy that targets CD19 surface antigens on B cells. BiTE ® molecules fight cancer by helping the body's immune system detect and target malignant cells by engaging T cells (a type of white blood cell capable of killing other cells perceived as threats) to cancer cells. By bringing T cells near cancer cells, the T cells can inject toxins and trigger cancer cell death (apoptosis). BiTE ® immuno-oncology therapies are currently being investigated for their potential to treat a wide variety of cancers. BLINCYTO was granted Breakthrough Therapy and Priority Review designations by the U.S. FDA and is approved in the U.S. for the treatment of: In the European Union (EU), BLINCYTO is indicated as monotherapy for the treatment of: BLINCYTO ® IMPORTANT SAFETY INFORMATION WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGICAL TOXICITIES including IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME Contraindications BLINCYTO ® is contraindicated in patients with a known hypersensitivity to blinatumomab or to any component of the product formulation. Warnings and Precautions Adverse Reactions Dosage and Administration Guidelines INDICATIONS BLINCYTO ® (blinatumomab) is indicated for the treatment of CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients one month and older with: Please see BLINCYTO ® full Prescribing Information , including BOXED WARNINGS. About Bispecific T-Cell Engager (BiTE ® ) Technology BiTE technology is a targeted immuno-oncology platform that is designed to engage a patient's own T cells to any tumor-specific antigen, activating the cytotoxic potential of T cells to eliminate detectable cancer. The BiTE immuno-oncology platform has the potential to treat different cancer types through tumor-specific antigens. The BiTE platform has a goal of leading to off-the-shelf solutions, which have the potential to make innovative T-cell treatment available to all providers when their patients need it. For more than a decade, Amgen has been advancing this innovative technology, which has demonstrated strong efficacy in hematological malignancies and now a solid tumor with the approval of IMDELLTRA. Amgen remains committed to progressing multiple BiTE molecules across a broad range of hematologic and solid tumor malignancies, paving the way for additional applications in more tumor types. Amgen is further investigating BiTE technology with the goal of enhancing patient experience and therapeutic potential. To learn more about BiTE technology, visit BiTE ® Technology 101 . About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions . Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ® , and it is also part of the Nasdaq-100 Index ® , which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. For more information, visit Amgen.com and follow Amgen on X , LinkedIn , Instagram , TikTok , YouTube and Threads . Amgen Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla ® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), Amgen's acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on Amgen's acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on Amgen's business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including its most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. No forward-looking statement can be guaranteed and actual results may differ materially from those Amgen projects. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for Amgen to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and Amgen expects similar variability in the future. Even when clinical trials are successful, regulatory authorities may question the sufficiency for approval of the trial endpoints Amgen has selected. Amgen develops product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as Amgen may have believed at the time of entering into such relationship. Also, Amgen or others could identify safety, side effects or manufacturing problems with its products, including its devices, after they are on the market. Amgen's results may be affected by its ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing its products and global economic conditions. In addition, sales of Amgen's products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, Amgen's research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Amgen's business may be impacted by government investigations, litigation and product liability claims. In addition, Amgen's business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If Amgen fails to meet the compliance obligations in the corporate integrity agreement between Amgen and the U.S. government, Amgen could become subject to significant sanctions. Further, while Amgen routinely obtains patents for its products and technology, the protection offered by its patents and patent applications may be challenged, invalidated or circumvented by its competitors, or Amgen may fail to prevail in present and future intellectual property litigation. Amgen performs a substantial amount of its commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depends on third parties for a portion of its manufacturing activities, and limits on supply may constrain sales of certain of its current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for Amgen's manufacturing activities, the distribution of Amgen's products, the commercialization of Amgen's product candidates, and Amgen's clinical trial operations, and any such events may have a material adverse effect on Amgen's product development, product sales, business and results of operations. Amgen relies on collaborations with third parties for the development of some of its product candidates and for the commercialization and sales of some of its commercial products. In addition, Amgen competes with other companies with respect to many of its marketed products as well as for the discovery and development of new products. Further, some raw materials, medical devices and component parts for Amgen's products are supplied by sole third-party suppliers. Certain of Amgen's distributors, customers and payers have substantial purchasing leverage in their dealings with Amgen. The discovery of significant problems with a product similar to one of Amgen's products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on its business and results of operations. Amgen's efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology Amgen has acquired, may not be successful. There can be no guarantee that Amgen will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. Amgen may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of Amgen's information technology systems could compromise the confidentiality, integrity and availability of Amgen's systems and Amgen's data. Amgen's stock price may be volatile and may be affected by a number of events. Amgen's business and operations may be negatively affected by the failure, or perceived failure, of achieving its environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect Amgen's business and operations. Global economic conditions may magnify certain risks that affect Amgen's business. Amgen's business performance could affect or limit the ability of the Amgen Board of Directors to declare a dividend or its ability to pay a dividend or repurchase its common stock. Amgen may not be able to access the capital and credit markets on terms that are favorable to it, or at all. Any scientific information discussed in this news release relating to new indications for Amgen's products is preliminary and investigative and is not part of the labeling approved by the U.S. Food and Drug Administration for the products. The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses. CONTACT: Amgen, Thousand Oaks Elissa Snook , 609-251-1407 (media) Justin Claeys , 805-313-9775 (investors) References View original content to download multimedia: https://www.prnewswire.com/news-releases/blincyto-blinatumomab-added-to-chemotherapy-significantly-improves-survival-in-newly-diagnosed-pediatric-patients-with-b-cell-precursor-acute-lymphoblastic-leukemia-b-all-302325381.html SOURCE Amgensnake online game 。

Mid-Penn Capital boys basketball preview: picks, predictions and preseason MVPs

NEW YORK — President-elect Donald Trump’s lawyers formally asked a judge Monday to throw out his hush money criminal conviction , arguing continuing the case would present unconstitutional “disruptions to the institution of the Presidency.“ In a filing made public Tuesday, Trump’s lawyers told Manhattan Judge Juan M. Merchan that dismissal is warranted because of the “overwhelming national mandate granted to him by the American people on November 5, 2024.” They also cited President Joe Biden’s recent pardon of his son, Hunter Biden, who was convicted of tax and gun charges . “President Biden asserted that his son was ‘selectively, and unfairly, prosecuted,’ and ‘treated differently,’" Trump’s legal team wrote. The Manhattan district attorney, they claimed, engaged in the type of political theater "that President Biden condemned.” Prosecutors will have until Dec. 9 to respond. They have said they will fight any efforts to dismiss the case but indicated a willingness to delay the sentencing until after Trump’s second term ends in 2029. Former President Donald Trump walks to make comments to members of the news media May 30 after a jury convicted him of felony crimes for falsifying business records in a scheme to illegally influence the 2016 election at Manhattan Criminal Court in New York. In their filing Monday, Trump's attorneys dismissed the idea of holding off sentencing until Trump is out of office as a “ridiculous suggestion.” Following Trump’s election victory last month, Merchan halted proceedings and indefinitely postponed his sentencing, previously scheduled for late November, to allow the defense and prosecution to weigh in on the future of the case. He also delayed a decision on Trump’s prior bid to dismiss the case on immunity grounds. Trump has been fighting for months to reverse his conviction on 34 counts of falsifying business records to conceal a $130,000 payment to porn actor Stormy Daniels to suppress her claim that they had sex a decade earlier. He says they did not and denies wrongdoing. Taking a swipe at Bragg and New York City, as Trump often did throughout the trial, the filing argues that dismissal would also benefit the public by giving him and “the numerous prosecutors assigned to this case a renewed opportunity to put an end to deteriorating conditions in the City and to protect its residents from violent crime.” Clearing Trump, the lawyers added, also would allow him to “to devote all of his energy to protecting the Nation.” The defense filing was signed by Trump lawyers Todd Blanche and Emil Bove, who represented Trump during the trial and since were selected by the president-elect to fill senior roles at the Justice Department. A dismissal would erase Trump’s historic conviction, sparing him the cloud of a criminal record and possible prison sentence. Trump is the first former president to be convicted of a crime and the first convicted criminal to be elected to the office. Trump takes office Jan. 20. Merchan hasn’t set a timetable for a decision. Merchan could also decide to uphold the verdict and proceed to sentencing, delay the case until Trump leaves office, wait until a federal appeals court rules on Trump’s parallel effort to get the case moved out of state court or choose some other option. Prosecutors cast the payout as part of a Trump-driven effort to keep voters from hearing salacious stories about him. Trump’s then-lawyer Michael Cohen paid Daniels. Trump later reimbursed him, and Trump’s company logged the reimbursements as legal expenses — concealing what they really were, prosecutors alleged. Trump pledged to appeal the verdict if the case is not dismissed. He and his lawyers said the payments to Cohen were properly categorized as legal expenses for legal work. A month after the verdict, the Supreme Court ruled that ex-presidents can’t be prosecuted for official acts — things they did in the course of running the country — and that prosecutors can’t cite those actions to bolster a case centered on purely personal, unofficial conduct. Trump’s lawyers cited the ruling to argue that the hush money jury got some improper evidence, such as Trump’s presidential financial disclosure form, testimony from some White House aides and social media posts made during his first term. Prosecutors disagreed and said the evidence in question was only “a sliver” of their case. If the verdict stands and the case proceeds to sentencing, Trump’s punishments would range from a fine to probation to up to four years in prison — but it’s unlikely he’d spend any time behind bars for a first-time conviction involving charges in the lowest tier of felonies. Because it is a state case, Trump would not be able to pardon himself once he returns to office. Presidential pardons apply only to federal crimes. Republican presidential nominee former President Donald Trump arrives at an election night watch party at the Palm Beach Convention Center, Wednesday, Nov. 6, 2024, in West Palm Beach, Fla. (AP Photo/Evan Vucci) Republican presidential nominee former President Donald Trump speaks as Melania Trump looks on at an election night watch party, Wednesday, Nov. 6, 2024, in West Palm Beach, Fla. (AP Photo/Alex Brandon) Republican presidential nominee former President Donald Trump speaks as former first lady Melania Trump listens after they voted on Election Day at the Morton and Barbara Mandel Recreation Center, Tuesday, Nov. 5, 2024, in Palm Beach, Fla. (AP Photo/Evan Vucci) Republican presidential nominee former President Donald Trump speaks as former first lady Melania Trump listens after they voted on Election Day at the Morton and Barbara Mandel Recreation Center, Tuesday, Nov. 5, 2024, in Palm Beach, Fla. (AP Photo/Evan Vucci) Republican presidential nominee former President Donald Trump speaks as former first lady Melania Trump listens after they voted on Election Day at the Morton and Barbara Mandel Recreation Center, Tuesday, Nov. 5, 2024, in Palm Beach, Fla. (AP Photo/Evan Vucci) Republican presidential nominee former President Donald Trump speaks after voting on Election Day at the Morton and Barbara Mandel Recreation Center, Tuesday, Nov. 5, 2024, in Palm Beach, Fla. (AP Photo/Evan Vucci) Republican presidential nominee former President Donald Trump speaks after voting on Election Day at the Morton and Barbara Mandel Recreation Center, Tuesday, Nov. 5, 2024, in Palm Beach, Fla. (AP Photo/Evan Vucci) Republican presidential nominee former President Donald Trump speaks as former first lady Melania Trump listens after they voted on Election Day at the Morton and Barbara Mandel Recreation Center, Tuesday, Nov. 5, 2024, in Palm Beach, Fla. (AP Photo/Evan Vucci) Republican presidential nominee former President Donald Trump speaks after voting on Election Day at the Morton and Barbara Mandel Recreation Center, Tuesday, Nov. 5, 2024, in Palm Beach, Fla. (AP Photo/Evan Vucci) Republican presidential nominee former President Donald Trump, joined by, from right, Melania Trump and Barron Trump, arrives to speaks at an election night watch party, Wednesday, Nov. 6, 2024, in West Palm Beach, Fla. (AP Photo/Alex Brandon) Republican presidential nominee former President Donald Trump arrives to speak at an election night watch party, Wednesday, Nov. 6, 2024, in West Palm Beach, Fla. (AP Photo/Alex Brandon) Republican presidential nominee former President Donald Trump arrives at an election night watch party at the Palm Beach Convention Center, Wednesday, Nov. 6, 2024, in West Palm Beach, Fla. (AP Photo/Evan Vucci) Republican presidential nominee former President Donald Trump speaks at an election night watch party, Wednesday, Nov. 6, 2024, in West Palm Beach, Fla. (AP Photo/Alex Brandon) Republican presidential nominee former President Donald Trump speaks at an election night watch party, Wednesday, Nov. 6, 2024, in West Palm Beach, Fla. (AP Photo/Alex Brandon) Republican presidential nominee former President Donald Trump arrives at an election night watch party at the Palm Beach Convention Center, Wednesday, Nov. 6, 2024, in West Palm Beach, Fla. (AP Photo/Evan Vucci) Republican presidential nominee former President Donald Trump speaks at an election night watch party, Wednesday, Nov. 6, 2024, in West Palm Beach, Fla. (AP Photo/Alex Brandon) Republican presidential nominee former President Donald Trump and former first lady Melania Trump walk after voting on Election Day at the Morton and Barbara Mandel Recreation Center, Tuesday, Nov. 5, 2024, in Palm Beach, Fla. (AP Photo/Evan Vucci) Republican presidential nominee former President Donald Trump and former first lady Melania Trump walk after voting on Election Day at the Morton and Barbara Mandel Recreation Center, Tuesday, Nov. 5, 2024, in Palm Beach, Fla. (AP Photo/Evan Vucci) Republican presidential nominee former President Donald Trump arrives at an election night watch party at the Palm Beach Convention Center, Wednesday, Nov. 6, 2024, in West Palm Beach, Fla. (AP Photo/Evan Vucci) Republican presidential nominee former President Donald Trump, with Melania Trump and Barron Trump, arrives to speak at an election night watch party, Wednesday, Nov. 6, 2024, in West Palm Beach, Fla. (AP Photo/Evan Vucci) Republican presidential nominee former President Donald Trump speaks at an election night watch party, Wednesday, Nov. 6, 2024, in West Palm Beach, Fla. (AP Photo/Julia Demaree Nikhinson) Republican Presidential nominee former President Donald Trump arrives with former first lady Melania Trump and son Barron Trump at the Palm Beach County Convention Center during an election night watch party, Wednesday, Nov. 6, 2024, in West Palm Beach, Fla. (AP Photo/Lynne Sladky) Republican presidential nominee former President Donald Trump speaks after voting on Election Day at the Morton and Barbara Mandel Recreation Center, Tuesday, Nov. 5, 2024, in Palm Beach, Fla. (AP Photo/Evan Vucci) Republican presidential nominee former President Donald Trump visits his campaign headquarters, Tuesday, Nov. 5, 2024, in West Palm Beach, Fla. (AP Photo/Evan Vucci) Republican Presidential nominee former President Donald Trump arrives with =former first lady Melania Trump and son Barron Trump at the Palm Beach County Convention Center during an election night watch party, Wednesday, Nov. 6, 2024, in West Palm Beach, Fla. (AP Photo/Lynne Sladky) Republican presidential nominee former President Donald Trump arrives at an election night watch party at the Palm Beach Convention Center, Wednesday, Nov. 6, 2024, in West Palm Beach, Fla. (AP Photo/Evan Vucci) Sign up for our Crime & Courts newsletter Get the latest in local public safety news with this weekly email.Visual Analytics Market: $7.58B in 2022, Forecast to Reach $29.29B by 2031Costco has announced it will stop selling books at most of its locations across the U.S. starting next year. The company said books will only return during holiday seasons, and intermittently outside of that. Costco said the change is being made because stocking books on tables is labor-intensive and must be done by hand. It also comes as more consumers buy their books from Amazon instead of brick-and-mortar stores. According to a survey by Statista Consumer Insights published earlier this year, 71% of people said they purchased a book from the online retailer rather than Barnes and Noble, Target or Costco.

None

Costco to stop selling books at most US locations starting next year

Trump's DEA Pick Chad Chronister Drops Out: What We KnowHOUSTON (AP) — An elaborate parody appears to be behind an effort to resurrect Enron, the Houston-based energy company that exemplified the worst in American corporate fraud and greed after it went bankrupt in 2001. If its return is comedic, some former employees who lost everything in Enron’s collapse aren’t laughing. “It’s a pretty sick joke and it disparages the people that did work there. And why would you want to even bring it back up again?” said former Enron employee Diana Peters, who represented workers in the company’s bankruptcy proceedings. Here’s what to know about the history of Enron and the purported effort to bring it back. Once the nation’s seventh-largest company, Enron filed for bankruptcy protection on Dec. 2, 2001, after years of accounting tricks could no longer hide billions of dollars in debt or make failing ventures appear profitable. The energy company's collapse put more than 5,000 people out of work, wiped out more than $2 billion in employee pensions and rendered $60 billion in Enron stock worthless. Its aftershocks were felt throughout the energy sector. Twenty-four Enron executives , including former CEO Jeffrey Skilling , were eventually convicted for their roles in the fraud. Enron founder Ken Lay’s convictions were vacated after he died of heart disease following his 2006 trial. On Monday — the 23rd anniversary of the bankruptcy filing — a company representing itself as Enron announced in a news release that it was relaunching as a “company dedicated to solving the global energy crisis.” It also posted a video on social media, advertised on at least one Houston billboard and a took out a full-page ad in the Houston Chronicle In the minute-long video that was full of generic corporate jargon, the company talks about “growth” and “rebirth.” It ends with the words, “We’re back. Can we talk?” Enron's new website features a company store, where various items featuring the brand's tilted “E” logo are for sale, including a $118 hoodie. In an email, company spokesperson Will Chabot said the new Enron was not doing any interviews yet, but that "We’ll have more to share soon.” Signs point to the comeback being a joke. In the “terms of use and conditions of sale” on the company's website, it says “the information on the website about Enron is First Amendment protected parody, represents performance art, and is for entertainment purposes only.” Documents filed with the U.S. Patent and Trademark Office show that College Company, an Arkansas-based LLC, owns the Enron trademark. The co-founder of College Company is Connor Gaydos, who helped create a joke conspiracy theory that claims all birds are actually surveillance drones for the government. Peters said that since learning about the “relaunch” of Enron, she has spoken with several other former employees and they are also upset by it. She said the apparent stunt was “in poor taste.” “If it’s a joke, it’s rude, extremely rude. And I hope that they realize it and apologize to all of the Enron employees,” Peters said. Peters, who is 74 years old, said she is still working in information technology because “I lost everything in Enron, and so my Social Security doesn’t always take care of things I need done.” “Enron’s downfall taught us critical lessons about corporate ethics, accountability, and the consequences of unchecked ambition. Enron’s legacy was the employees in the trenches. Leave Enron buried,” she said. This story was corrected to fix the spelling of Ken Lay’s first name, which had been misspelled “Key.” Follow Juan A. Lozano on X at https://x.com/juanlozano70

HARRISBURG, Pa. (AP) — President-elect Donald Trump is underscoring his intention to block the purchase of U.S. Steel by Japanese steelmaker Nippon Steel Corp. , and he's pledging to use tax incentives and tariffs to strengthen the iconic American steelmaker. Trump had vowed early in the presidential campaign that he would “instantaneously” block the deal, and he reiterated that sentiment in a post on his Truth Social platform on Monday night. “I am totally against the once great and powerful U.S. Steel being bought by a foreign company” and will use tax incentives and tariffs to make U.S. Steel “Strong and Great Again, and it will happen FAST!” he wrote. “As President," he continued, "I will block this deal from happening. Buyer Beware!!!” President Joe Biden , like Trump, also opposes Nippon Steel's purchase of Pittsburgh-based U.S. Steel. Biden’s White House in September said that it had yet to see a report from the secretive Committee on Foreign Investment in the United States , which was reviewing the transaction for national security concerns. The committee, which is chaired by the treasury secretary and includes other Cabinet members, can recommend that the president block a transaction, and federal law gives the president that power. Ahead of the November election, the proposed merger carried political importance in Pennsylvania, a critical swing state that Trump eventually won. Biden publicly sided with the United Steelworkers, the labor union, in seeking to reject the deal. When he announced his opposition in a March statement, Biden said: “U.S. Steel has been an iconic American steel company for more than a century, and it is vital for it to remain an American steel company that is domestically owned and operated.” Nippon Steel has said it is the only company that can make the necessary investment in U.S. Steel's factories and strengthen the American steel industry. Both Nippon Steel and U.S. Steel on Tuesday released statements in support of the acquisition. "This transaction should be approved on its merits. The benefits are overwhelmingly clear. Our communities, customers, investors, and employees strongly support this transaction, and we will continue to advocate for them and adherence to the rule of law," U.S. Steel said. The deal follows a long stretch of protectionist U.S. tariffs that analysts say has helped reinvigorate domestic steel, including U.S. Steel. U.S. Steel's shareholders have approved the deal, but the United Steelworkers oppose it. In a statement Tuesday, the union said the deal carries “serious long-term implications for U.S. economic and national security.” “It’s clear that President Trump understands the vital role a strong domestic steel industry plays in our national security, as well as the importance of the jobs and communities the industry supports," the union said. The deal has drawn bipartisan opposition in the U.S. Senate, including from the incoming vice president, Republican Sen. JD Vance of Ohio, although the federal government's objections to the deal have drawn criticism that the opposition is political. Some U.S. Steel workers would prefer Nippon Steel acquire the company, given that it appears to have a better financial balance sheet than another potential buyer, Cleveland-Cliffs. U.S. Steel “provided a very, very good life for our families for a lot of years,” said Jack Maskil, a vice president at the Steelworkers local branch in West Mifflin, Pennsylvania. “And we feel that with the Nippon deal that a lot more families for futures to come will be able to share the same.” West Mifflin Mayor Chris Kelly said he met with Nippon Steel executives and found himself satisfied by their commitments. Located southeast of Pittsburgh, West Mifflin is home to U.S. Steel's Mon Valley Works–Irvin Plant. “There’s no question in my mind that it’s the best deal moving forward,” Kelly said at a panel hosted on Tuesday by the conservative think tank Hudson Institute, where Maskil was also speaking. The Biden administration committee vetting the merger is scheduled later this month to decide on the acquisition or possibly extend the ongoing review. William Chou, a deputy director at the Hudson Institute specializing in relations with Japan, said that "President-elect Trump's view on the deal are important." But given the upcoming deadline, “It's up to President Biden to recognize how this deal will advance the interests of future generations of U.S. Steel union steelworkers.” Trump’s statement came two weeks after Nippon Steel’s vice chairman, Takahiro Mori, visited Pittsburgh and Washington to meet with lawmakers, local officials and workers in an ongoing persuasion campaign. That campaign has included Nippon Steel's promises to boost its capital commitments beyond the original deal and, more recently, a pledge that it won’t import steel slabs that would compete with U.S. Steel’s blast furnaces. As part of its proposed $14.9 billion purchase of U.S. Steel, Nippon Steel also pledged to invest at least $1.4 billion in USW-represented facilities, not to conduct layoffs or plant closings during the term of the basic labor agreement, and to protect the best interests of U.S. Steel in trade matters. Boak reported from Washington.World Bank estimates total external debt stocks at $130.847bn by end 2023

It was a fine first win for Ruud van Nistelrooy , and perhaps one final defeat for Julen Lopetegui. Leicester marked Van Nistelrooy’s first match in charge of the team by surging to a 3-1 win over Lopetegui's West Ham in the Premier League on Tuesday. Van Nistelrooy, the former Manchester United striker, is back in English soccer this time as a manager, with Leicester taking something of a gamble on the Dutchman after his brief and impressive spell as interim coach at United this season following Erik ten Hag's departure. He faces the tough task of keeping Leicester, one of the top candidates for relegation, in the top division. For that to happen, he’s likely to need goals from Jamie Vardy — and the 37-year-old former England international delivered immediately. Nine years after breaking Van Nistelrooy’s record for scoring in consecutive games, Vardy scored the first goal of the Dutchman’s tenure at Leicester by beating the offside trap and slotting home a finish with less than two minutes gone. Morocco midfielder Bilal El Khannouss supplied the pass for Vardy’s goal and scored himself with a low shot in the 61st minute to make it 2-0. Patson Daka added a third for Leicester in the 90th minute, before a stoppage-time consolation by West Ham substitute Niclas Füllkrug. “We are very happy with the new manager," El Khannouss said of Van Nistelrooy. “He arrived two days ago, and there’s a new dynamic in the group.” Van Nistelrooy praised the “spirit and energy” in his team. “The foundation for us going forward is everyone working their socks off, fighting for every inch and defending together,” he said. “We can look further then, and they did that in an unbelievable way.” This dismal result for West Ham came three days after its 5-2 thrashing at home by Arsenal , which piled more pressure of Lopetegui early in the former Spain and Real Madrid coach's first season with the London club. West Ham's disgruntled traveling fans chanted "You’re getting sacked in the morning” toward Lopetegui during the second half — even if his team dominated large parts of the game but only had one goal to show from 31 shots on goal. “We're very frustrated but in the same way I can say nothing about the players — they fight until the end,” Lopetegui said. "It’s not easy to explain football some days.” West Ham has lost seven of its 14 games so far and is in 14th place in the 20-team league, one spot above Leicester. Crystal Palace won for just the second time in the league this season, beating relegation rival Ipswich 1-0 to pull clear of the bottom three. Jean-Philippe Mateta scored the goal in the 59th minute. Palace’s only other league victory was against Tottenham in October. While Ipswich stayed in next-to-last place, Palace moved three points above the relegation zone. Much of the focus ahead of the game was on the teams’ captains , Sam Morsy of Ipswich and Marc Guehi of Palace, during another round when the Premier League was celebrating LGBTQ+ inclusion in its campaign to promote equality and diversity. For the second straight game, Morsy chose against wearing a rainbow armband issued to the captain of each of the 20 teams in the league. He has made the decision “due to his religious beliefs,” Ipswich says. Guehi did wear the rainbow armband but defied Football Association rules by writing a religious message on the item. The message read “Jesus loves you” — using a heart sign instead of the word “loves.” During the match against Newcastle on Saturday, Guehi wrote “I love Jesus” — and was later contacted by the FA for acting in contravention of its regulations. AP soccer: https://apnews.com/hub/soccerDow leaps over 400 points to record close as investors welcome signs of robust economy

ATLANTA — On Jan. 18 and 19 the AT&T Playoff Playlist Live! will be held at State Farm Arena in advance of the College Football Playoff national championship on Jan. 20. The star-studded lineup was announced Thursday at a news conference at Mercedes-Benz Stadium. Performances will include Lil Wayne and GloRilla on Saturday; and Camila Cabello, Myles Smith and Knox on Sunday. On game day, the Allstate Championship Tailgate, taking place just outside Mercedes-Benz Stadium in the Home Depot Backyard, will feature country acts on the Capital One Music Stage, including global superstar Kane Brown and iHeartCountry “On The Verge” artist Ashley Cooke. The concerts are just two of the festivities visiting fans can enjoy in the days leading up to the big game. The fan experience for both ticket holders and the general public has been a focus for event planners. All weekend long, an estimated 100,000 people from across the country are expected to attend fan events preceding kickoff. “It will be an opportunity for fans of all ages to come together to sample what college football is all about, and you don’t have to have a ticket to the game to be a part of it,” said Bill Hancock, executive director of the CFP in a press release. “We’ve worked closely with the Atlanta Football Host Committee to develop fan-friendly events that thousands will enjoy come January.” On Saturday, Jan. 18, Playoff Fan Central will open at the Georgia World Congress Center in downtown Atlanta. The free, family-friendly experience will include games, clinics, pep rallies, special guest appearances, autograph signings and exhibits celebrating college football and its history. That day, fans can also attend Media Day, presented by Great Clips, which will feature one-hour sessions with student-athletes and coaches from each of the College Football Playoff national championship participating teams. ESPN and social media giants X, Facebook, Instagram and TikTok will be taping live broadcasts from the event. On Sunday, Jan. 19, the Trophy Trot, both a 5K and 10K race, will wind its way through the streets of downtown Atlanta. Each Trophy Trot participant will receive a T-shirt and finisher’s medal. Participants can register at atlantatrackclub.org . On Sunday evening, the Georgia Aquarium will host the Taste of the Championship dining event, which offers attendees the opportunity to indulge in food and drink prepared by local Atlanta chefs. This premium experience serves as an elevated exploration of local cuisine on the eve of the national championship. Tickets to the Taste of the Championship event are available on etix.com . Atlanta is the first city ever to repeat as host for the CFP national championship. The playoff was previously held in Atlanta in 2018. “We are honored to be the first city to repeat as host for the CFP national championship and look forward to welcoming college football fans from around the country in January,” said Dan Corso, president of the Atlanta Sports Council and Atlanta Football Host Committee. “This event gives us another opportunity to showcase our incredible city.” The College Football Playoff is the event that crowns the national champion in college football. The quarterfinals and semifinals rotate annually among six bowl games — the Goodyear Cotton Bowl Classic, Vrbo Fiesta Bowl, Capital One Orange Bowl, Chick-fil-A Peach Bowl, Rose Bowl Game presented by Prudential and the Allstate Sugar Bowl. This year’s quarterfinals will take place on Dec. 31, 2024 and Jan. 1, 2025, while the semifinals will be Jan. 9-10, 2025. The CFP national championship will be Monday, Jan. 20, 2025, at Mercedes-Benz Stadium. For additional information on the College Football Playoff, visit CollegeFootballPlayoff.com . Get local news delivered to your inbox!

Scented candles are a fabulous Christmas gift idea , particularly for those who seem to have everything. They not only make the home smell divine but also create a cosy ambience and serve as a luxurious indulgence that most people wouldn't splurge on themselves. As a self-confessed candle hoarder, I've burned through hundreds in my lifetime and always have a stash ready to go. Now that my autumnal scents have been used up, I'm reaching for festive fragrances as we approach Christmas. Think rich spices, fresh pine and seasonal citrus fruits, all ideally presented in a jar that's a bit special or sparkly. Here are my top picks for every budget... Yankee Candle London Christmas Tea Signature Large Jar 567g: Was £29.99, now £20.99 from Debenhams NEOM Winter Wellbeing Candle Trio 3 x 75g: Was £48, now £38.40 from LookFantastic Diptyque Sapin Classic Candle 190g: £68 from Diptyque Yankee Candle Collection Gift Set: Was £60, now £29.50 from Boots The White Company Winter Mercury Luxury Votive Candle 95g: £16 from LookFantastic NEST New York Holiday Classic Candle & Diffuser Set: £95 from Sephora M&S London Light Up Scented Candle: £10 from Marks & Spencer ESPA Winter Spice Candle 200g: Was £45, now £40.50 from LookFantastic Liz Earle Spiced Bitter Orange Botanical Candle 220g: Was £37, now £27.75 from Liz Earle Space NK Shimmering Spice 3-Wick Scented Candle 400g: £42 from Space NK The White Collection Gingerbread Scented Candle 160g: £8 from Boots Lords Abernethy Forest Winter 3 Wick Candle 650g: £62 from Lords Was £29.99, now £20.99 from Debenhams Big, heavy and strongly scented, Yankee Candles are guaranteed crowd-pleasers. Its Christmas collection is inspired by festive celebrations around the world, including this London Christmas Tea fragrance , with notes of ginger, black tea, cinnamon and woods. Was £48, now £38.40 from LookFantastic I'm a huge fan of NEOM's candles, and this year's Christmas collection is just stunning, with gorgeous packaging and scents that really fill the home. Unsure which scent to go for? Buy this three-piece set , which contains a 75g candle of each: cinnamon-y Christmas Wish, pine-inspired Perfect Peace, and warm, woody Cosy NIghts. £68 from Diptyque Scented candles don't come much better than Diptyque's and I defy you to find anyone who wouldn't be blown away to receive this as a Christmas present. Sapin – a fresh, earthy, pine tree scent – is one of the brand's most popular at Christmas, and you'll smell it as soon as you open the box. This year's has been designed by artist Lucy Sparrow and features a felt decoration and luxe gold lid. Was £60, now £29.50 from Boots Another Yankee Candle idea, but here's a way to get eight different ones for less than £30 . This gift set usually costs £60 but is currently down to £29.50 as part of Boots' Star Gifts pre-Christmas sales . This means that each product inside – one medium jar, two tumblers, three filled votives and two wax melts – could technically be valued at £3.68. White Spruce & Grapefruit is a lovely fresh, zingy scent, while Black Cherry and Christmas Cookie are perfect for those who love gourmands. £16 from LookFantastic For a candle that looks as good as it smells, go for this chic little White Company votive . What is lacks in size, it makes up for in scent, as it smells exactly like mulled wine tastes: warming, spicy, lightly fruity. Once it's burned down, clean it out and use it as a tea light holder. £95 from Sephora This NEST candle is what we imagine Kris Jenner's house smells like at Christmas; with notes of pomegranate, pine, vanilla and amber, it just smells (and looks) expensive. Your best option is to buy this candle and diffuser set together – it makes the ultimate gift. £10 from Marks & Spencer Another favourite every year, M&S's light up candles are always a hit, often selling out in advance of the festive season; just light the candle in the centre and LED lights will turn on, illuminating a beautiful London scene. It's not the strongest smelling one of the bunch, but what it lacks in powerful aroma it makes up for in dazzling style. The particular London design was sold out online at the time of writing (although you may find it in stores still), but this other light up design is similar . Was £45, now £40.50 from LookFantastic Another that hits your as soon as you open its elaborate box, and another with strong whiffs of mulled wine: sweet orange, clove, cinnamon and ginger. This one has a slightly more spa-like vibe though , high in mood-boosting essential oils, and a smart gold lid. Was £37, now £27.75 from Liz Earle Want a candle that'll see you through the festive period and into spring? This Liz Earle offering is the one for you. Its design is refreshingly spangle-free for a Christmas candle, and its spiced orange scent smells as fresh as it does festive. £42 from Space NK High up on many a beauty editor's Christmas wish list every year, Space NK's stunning Shimmering Spice candle has acquired cult status, with notes of cinnamon, cedar and all spice. I think this big three-wicker is good value compared to many others, but it's also available in 75g (£18) and 190g (£28) . £8 from Boots One for those with a sweet tooth or fans of the current gourmand fragrance trend, this smells like a freshly baked gingerbread house (albeit fairly faintly). For £8 though, it's good value, and I'm impressed that it comes with a metal lid/stand. £62 from Lords This lovely home fragrance brand is a fairly new discovery to me, and I've fallen in love with its scents inspired by locations around the world – including Abernethy Forest in Scotland, with notes of pine needle, cedarwood, eucalyptus, patchouli, peppermint, lavandin and fir balsam. The 225g jar I have is currently out of stock, but the larger three-wick one is still available .Trump vows to block Japanese steelmaker from buying US Steel, pledges tax incentives and tariffs

New disability ministers will ‘champion’ inclusion and accessibility – minister